Global Vision

◆Research and Development Policy

Since its foundation in 1939, Nippon Zoki Pharmaceutical has been consistently involved in all aspects of pharmaceutical operations, from drug discovery research to development, manufacturing, and marketing. In particular, for our mainstay in-house product, the pain treatment Neurotropin, we have continued research and development for many years even after its launch, guided by our approach to lifecycle drug development, with a view to expanding indications and other related developments.

Building on the trust we have earned from patients and healthcare professionals, as well as the clinical trial experience and know-how accumulated through numerous products, we are currently focusing our R&D efforts on the field of orthopedics, neuroscience centered on pain, and related therapeutic areas. Within these fields, we are taking on the challenge of developing pharmaceuticals, regenerative medicine products, and medical devices.

To continue creating new drugs and medical devices that can make meaningful contributions, our core approach is to identify promising opportunities on a global scale, work together with forerunners in each field to realize innovative solutions, and maximize their value. This approach forms the foundation of our R&D activities.

Under these policies, the R&D Headquarters serves as the core organization for new product creation, integrating and overseeing our former research and development functions. In addition to conducting licensing activities to in-license candidate products from research institutions and companies in Japan and overseas, the R&D Headquarters is responsible for clinical trials and regulatory-related procedures.

Our Research Division in Ono City, Hyogo Prefecture (Life Science Laboratories), the Development Division at our Osaka Head Office, and the development site in Tokyo work closely together to establish a framework in which all members collectively aim to advance candidate products from exploration through commercialization. Among these, the Research Division also functions as a hub for global information gathering and dissemination.

◆Partnerships with Overseas Companies

Licensing activities aimed at creating new products are being actively pursued with overseas companies. A representative example in the pharmaceutical field is a bone morphogenetic protein-2 (BMP-2) formulation currently under development in Japan for the treatment of lumbar degenerative disease, based on an agreement with CG Bio Co., Ltd. of South Korea. An application for regulatory approval is planned for fiscal year 2030.

In order to respond broadly to medical needs in the field of orthopedics, we are also engaged in the introduction and development of medical devices, with multiple projects involving overseas companies currently underway.

In addition, we are advancing discussions and evaluations with overseas companies regarding potential in-licensing opportunities for pharmaceuticals, regenerative medicine products, and medical devices across multiple candidate assets. Where the originating company has not yet pursued global development and such potential exists, we will explore global development in collaboration with the originating partner.

By expanding our pipeline to address unmet medical needs in patients and healthcare settings worldwide, we are committed to delivering innovative solutions as swiftly as possible.